As part of the preparations for the SPARKLE image re-evaluation, the new independent readers have successfully completed the training program according to plan. The image reading process has now started and the first patient images have been evaluated. The re-evaluation is on track to report headline results by May 2024, as previously communicated.

Ascelia Pharma has also interacted with the FDA in relation to the need for a re-evaluation. Based on this, no changes to the re-evaluation process were made.

“The most important factors for obtaining consistent results are the selection and training of readers, and the scheduling and monitoring of the image reading flow. In the re-evaluation, we have diligently developed these elements to ensure that reliable results will be obtained by May 2024”, says Andreas Norlin, CSO of Ascelia Pharma.

Ascelia Pharma successfully completed patient enrollment in the Phase 3 study for Orviglance in March 2023. In early August, it was discovered that high intra-reader variability in the study image scoring by the independent radiologists prevented evaluation of the efficacy data from SPARKLE. Due to this finding, a new evaluation of the images with new independent readers was decided and is now underway. The purpose of the re-evaluation of the SPARKLE images is to obtain a scientifically valid and reliable result from the SPARKLE study. A positive result would together with the other available data support a regulatory approval for Orviglance.

“We are dedicated to making Orviglance available for cancer patients with kidney impairment. Today’s announcement marks an important milestone towards being able to report efficacy results from SPARKLE. The planning and preparation phase of the re-evaluation is now completed, and the start of the image reading puts us on track for reporting results by May next year”, says Magnus Corfitzen, CEO of Ascelia Pharma.